High-throughput drug screen reveals HDAC and proteasome inhibitors as potent drug classes against synovial sarcoma. by Aimée N. Laporte (3617987)

Effect of follicular fluid (FF) supplementation during the maturation period on cumulus cell expansion. by Verónica M. Negrón-Pérez (20691412)

Percentage of increase in the area of cumulus oocyte complexes (COCs). by Verónica M. Negrón-Pérez (20691412)

Epac activation increased MYPT phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases breadth of Env-specific IgG response. by LaTonya D. Williams (3140490)

Opioid consumption data. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Prescription data. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Refill rate by surgical specialty. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Noncontinuous data on opioid use. by Wali U. Pirzada (22278071)

“…Orthopaedic Surgery patients saw a mean 45% reduction in prescription size from 462 MMEs (range: 50–7200 MMEs) to 197 MMEs (range: 25–2400 MMEs) (p < .001), while General Surgery patients experienced a mean 38% reduction from 100 MMEs (range: 25–150 MMEs) to 60 MMEs (range: 25–150 MMEs) (p < .001). …”

Antihypertensive effect and the underlying mechanisms of action of phytolaccagenin in rat models by Imran Ul Haq (12676309)

“…However, Nω-nitro-L-arginine methyl ester (L-NAME) (100 mg/kg) pretreatment modified the effect of phytolaccagenin on blood pressure with greater response. …”

Modulation of PIP₂ levels by PLC activity in INS-1 and RyR2^KO cells. by Kyle E. Harvey (4375987)

“…<b>E)</b> Quantification (AUC) of the decrease in plasma membrane GFP-C1-PLCdelta-PH fluorescence in control INS-1 cells and RyR2^KO cells in the presence or absence of 100 μM 2-APB. …”

Table_3_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

Table_1_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

Table_5_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

Image_1_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.JPEG by Martina Anna Maggioni (8568585)

Table_4_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

Table_2_The Advantage of Supine and Standing Heart Rate Variability Analysis to Assess Training Status and Performance in a Walking Ultramarathon.DOCX by Martina Anna Maggioni (8568585)

The effector functions of CHK-152 contribute to protection <i>in vivo</i>. by Pankaj Pal (404355)

“…Ch-CHK-152 mediated protection was significantly greater than ch-CHK-152 N297Q on days 7, 8, and 9 post infection for the 100 µg antibody dose, and at day 7 post infection for the 50 µg dose, as determined by the Kruskal-Wallace test with Bonferroni correction (<i>P</i><0.05). …”

Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia by Atham Ali (19345980)

“…Mean ± SD (<i>n</i> = 3).</p>…”